Table 2.

Cases of anti-GBM GN in HIV-infected patients

Study (Reference)	Age (yr)	Sex	CD4 Count (cells/ml)	Organs	SCr (mg/dl)	Renal Pathology	Treatment	Outcome	Anti-GBM Level		Complications
									Pre	Post
Monteiro et al. (3)	30	Male	495	Kidney	13.5	Necrotizing crescentic (50%) GN	PLEX × 14 d Corticosteroidsa Cyclophosphamide, 1.5 mg/kg per d	ESRD	68 U/ml	NA	NA
Wechsler et al. (4)	55	Male	305	Kidney	3.5	Necrotizing crescentic (10%) GN	PLEX × 14 d Corticosteroidsb	Resolution	8.6 EU/mlc	0 EU/ml	Nausea, vomiting, hematemesis
								SCr 1.1 mg/dl 6 wk after treatment
						IgA nephropathy	MMF IVIG Rituximab × 4 wk
Singh et al. (5)	33	Male	214	Kidney	19.3	Necrotizing crescentic GN	PLEX × 5 d	ESRD	361 AU/ml	40 AU/ml	Hypoxia (atypical pneumonia versus hemorrhage)
				Lung		ATN	Corticosteroidsd
Current report	42	Male	679	Kidney	1.89	Necrotizing crescentic GN	PLEX × 14 d Corticosteroidse Cyclophosphamide, 100 mg/d	ESRD	366 AU/mlf	104 AU/ml	EBV and CMV viremia

SCr, serum creatinine; anti-GBM pre and post, anti-GBM antibody titers before and 4 wk after treatment; PLEX, plasmapheresis; NA, not available; MMF, mycophenolate mofetil; IVIG, intravenous immunoglobulin; ATN, acute tubular necrosis;

^a1 mg/kg per day.

^b40 mg/d.

^cReference values, 0–5 EU/ml.

^dMethylprednisone, 1000 mg/d × 3 d; IVIG, 140 g (10% solution); rituximab, 375 mg/m² per wk × 4 wk.

^eMethylprednisolone, 750 mg/d × 1 d, 500 mg/d × 1 day, 250 mg/d × 1 day, then prednisone, 80 mg/d × 5 d, then 60 mg/d.

^fReference values, 0–19 AU/ml.